US2014113962A1PendingUtilityA1

Inhibitors of nitric oxide synthase

Assignee: MUSC FOUND FOR RES DEVPriority: Nov 25, 1997Filed: Jul 26, 2013Published: Apr 24, 2014
Est. expiryNov 25, 2017(expired)· nominal 20-yr term from priority
Inventors:Inderjit Singh
A61K 31/00A61K 31/20A61P 9/10A61K 31/472A61K 31/275A61K 31/661A61K 31/7076A61K 31/198A61K 31/343A61K 31/7056A61K 31/522A61K 31/40A61P 9/12A61K 31/366A61K 31/175A61K 31/137A61K 31/145A61K 31/4196C12N 9/99A61K 31/4015A61K 31/35A61K 31/352A61K 31/192
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP.

Claims

exact text as granted — not AI-modified
1 .- 65 . (canceled) 
     
     
         66 . A method for treatment of septic shock in a human patient suffering from septic shock, comprising administering a biologically effective amount of at least one induction suppressor of inducible nitric oxide synthase to said patient. 
     
     
         67 . The method of  claim 66 , wherein said induction suppressor of inducible nitric oxide synthase is an inhibitor of mevalonate synthesis, an inhibitor of Ras/Raf/MAP kinase pathway, an inhibitor of the farnesylation of Ras, an inhibitor of NF-kβ activation, an antioxidant, an enhancer of intracellular cAMP, an enhancer of protein kinase A (PKA) or a stimulator of AMP-activated protein kinase. 
     
     
         68 . The method of  claim 66 , wherein said induction suppressor of inducible nitric oxide synthase is selected from the group consisting of lovastatin, mevastatin, FPT inhibitor II, forskolin, rolipram, phenylacetate, N-acetyl cysteine, PDTC, 4-phenylbutyrate (4PBA), 5-aminoimmidazole-4-carboxamide ribonucleoside (AICAR), theophylline, papaverine, cAMP, 8-bromo-cAMP and (S)-cAMP. 
     
     
         69 .- 75 . (canceled)

Join the waitlist — get patent alerts

Track US2014113962A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.